RecruitingPHASE2, PHASE3NCT07058077
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Studying Rare hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Enlicitide Decanoate(drug)
- Enrollment
- 153 target
- Eligibility
- 6-17 years · All sexes
- Timeline
- 2025 – 2037
Study locations (21)
- Nemours/Alfred I. duPont Hospital for Children ( Site 0001), Wilmington, Delaware, United States
- Children's National Medical Center ( Site 0015), Washington D.C., District of Columbia, United States
- Excel Medical Clinical Trials ( Site 0008), Boca Raton, Florida, United States
- Children's Healthcare of Atlanta Cardiology ( Site 0026), Atlanta, Georgia, United States
- Monash Children s Hospital ( Site 1603), Clayton, Victoria, Australia
- UZ Antwerpen ( Site 0601), Edegem, Antwerpen, Belgium
- Universidade Federal Do Ceara ( Site 0201), Fortaleza, Ceará, Brazil
- Incor - Instituto do Coracao ( Site 0200), São Paulo, Brazil
- Beijing Anzhen Hospital. Capital Medical University ( Site 1917), Beijing, Beijing Municipality, China
- The Children's Hospital of Zhejiang University School of Medicine ( Site 1905), Hangzhou, Zhejiang, China
- Clinica de la Costa S.A.S. ( Site 0400), Barranquilla, Atlántico, Colombia
- Oncomédica S.A.S ( Site 0401), Montería, Departamento de Córdoba, Colombia
- Fundación Cardiovascular de Colombia ( Site 0402), Piedecuesta, Santander Department, Colombia
- Fundacion Valle del Lili ( Site 0403), Cali, Valle del Cauca Department, Colombia
- New Childrens Hospital ( Site 0800), Helsinki, Uusimaa, Finland
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07058077 on ClinicalTrials.govOther trials for Rare hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07470723The ORIGIN-FH StudyUniversity of Wisconsin, Madison
- RECRUITINGNANCT06960902Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)Nantes University Hospital
- RECRUITINGNCT06958315Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyNovartis Pharmaceuticals
- RECRUITINGNCT04529967Child-Parent Familial Hypercholesterolemia ScreeningChildren's Hospital of Fudan University
- RECRUITINGPHASE3NCT06597006Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaNovartis Pharmaceuticals
- RECRUITINGNCT06634160Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial HypercholesterolemiaNantes University Hospital
- RECRUITINGPHASE3NCT06597019Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT06331195An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)Hospital do Coracao